Cocrystal Historical Income Statement

COCP Stock

USD 2.69 0.44 19.56%

Historical analysis of Cocrystal Pharma income statement accounts such as Selling General Administrative of 4.1 M, Selling And Marketing Expenses of 8.9 M or Other Operating Expenses of 22.7 M can show how well Cocrystal Pharma performed in making a profits. Evaluating Cocrystal Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cocrystal Pharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cocrystal Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cocrystal Pharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

About Cocrystal Income Statement Analysis

Cocrystal Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cocrystal Pharma shareholders. The income statement also shows Cocrystal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cocrystal Pharma Income Statement Chart

At this time, Cocrystal Pharma's Selling And Marketing Expenses is relatively stable compared to the past year. As of 12/24/2024, Other Operating Expenses is likely to grow to about 22.7 M, while Selling General Administrative is likely to drop slightly above 4.1 M.

Depreciation And Amortization Selling General Administrative Selling And Marketing Expenses Gross Profit Other Operating Expenses Ebitda

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Cocrystal Pharma minus its cost of goods sold. It is profit before Cocrystal Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cocrystal Pharma. It is also known as Cocrystal Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Cocrystal Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cocrystal Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.At this time, Cocrystal Pharma's Selling And Marketing Expenses is relatively stable compared to the past year. As of 12/24/2024, Other Operating Expenses is likely to grow to about 22.7 M, while Selling General Administrative is likely to drop slightly above 4.1 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	14.2M	18.1M	3.4M	3.2M
Cost Of Revenue	239.5K	241.6K	15.2M	15.9M

Total Operating Expenses Cost Of Revenue

Cocrystal Pharma income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Research Development	Discontinued Operations	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Non Recurring
Depreciation And Amortization		-0.1	0.05	0.09	0.37	-0.15	-0.2	-0.21	0.2	-0.19	-0.1	-0.19	0.05	-0.3	0.09	0.15	-0.15	-0.14	-0.3	0.11	-0.2	-0.27	0.1	0.14
Interest Expense	-0.1		0.21	-0.48	0.37	-0.17	0.35	0.35	0.31	0.24	-0.21	0.28	-0.14	0.24	0.46	0.55	-0.29	-0.16	0.26	-0.35	0.53	0.03	-0.32	0.16
Selling General Administrative	0.05	0.21		0.03	0.06	0.23	-0.18	-0.13	-0.11	0.36	0.14	-0.23	-0.36	-0.28	-0.04	0.12	0.09	0.15	-0.26	-0.36	-0.12	0.05	0.33	-0.04
Selling And Marketing Expenses	0.09	-0.48	0.03		-0.49	0.22	-0.38	-0.39	-0.35	-0.08	0.22	-0.36	-0.04	-0.4	-0.23	-0.91	0.32	0.32	-0.27	0.41	-0.64	0.11	0.43	-0.33
Gross Profit	0.37	0.37	0.06	-0.49		-0.05	-0.02	-0.03	0.12	-0.61	0.11	-0.05	-0.06	-0.05	0.02	0.51	-0.13	-0.88	-0.08	-0.18	0.35	-0.82	-0.46	0.85
Other Operating Expenses	-0.15	-0.17	0.23	0.22	-0.05		-0.9	-0.89	-0.96	-0.09	0.97	-0.9	-0.15	-0.82	-0.9	-0.3	0.98	-0.04	-0.83	-0.03	-0.26	-0.01	-0.27	0.04
Operating Income	-0.2	0.35	-0.18	-0.38	-0.02	-0.9		0.99	0.91	0.26	-0.91	0.99	0.13	0.96	0.85	0.4	-0.92	0.1	0.96	-0.08	0.43	0.15	0.11	-0.09
Ebit	-0.21	0.35	-0.13	-0.39	-0.03	-0.89	0.99		0.92	0.27	-0.91	0.97	0.04	0.94	0.85	0.4	-0.91	0.1	0.94	-0.17	0.45	0.17	0.11	-0.1
Ebitda	0.2	0.31	-0.11	-0.35	0.12	-0.96	0.91	0.92		0.19	-0.95	0.9	0.06	0.82	0.88	0.46	-0.97	0.05	0.83	-0.12	0.37	0.05	0.16	-0.04
Cost Of Revenue	-0.19	0.24	0.36	-0.08	-0.61	-0.09	0.26	0.27	0.19		-0.31	0.26	0.13	0.25	0.25	0.19	-0.14	0.79	0.23	-0.05	-0.04	0.85	0.3	-0.8
Total Operating Expenses	-0.1	-0.21	0.14	0.22	0.11	0.97	-0.91	-0.91	-0.95	-0.31		-0.92	-0.18	-0.83	-0.91	-0.31	0.97	-0.23	-0.84	-0.03	-0.23	-0.21	-0.33	0.23
Income Before Tax	-0.19	0.28	-0.23	-0.36	-0.05	-0.9	0.99	0.97	0.9	0.26	-0.92		0.26	0.98	0.83	0.38	-0.91	0.12	0.98	0.05	0.36	0.15	0.14	-0.11
Total Other Income Expense Net	0.05	-0.14	-0.36	-0.04	-0.06	-0.15	0.13	0.04	0.06	0.13	-0.18	0.26		0.3	0.08	0.09	-0.13	0.11	0.27	0.88	-0.32	0.02	0.15	-0.11
Net Income	-0.3	0.24	-0.28	-0.4	-0.05	-0.82	0.96	0.94	0.82	0.25	-0.83	0.98	0.3		0.7	0.38	-0.82	0.09	0.98	0.07	0.38	0.15	0.05	-0.09
Income Tax Expense	0.09	0.46	-0.04	-0.23	0.02	-0.9	0.85	0.85	0.88	0.25	-0.91	0.83	0.08	0.7		0.34	-0.92	0.12	0.75	-0.05	0.31	0.13	0.28	-0.12
Total Revenue	0.15	0.55	0.12	-0.91	0.51	-0.3	0.4	0.4	0.46	0.19	-0.31	0.38	0.09	0.38	0.34		-0.41	-0.25	0.27	-0.35	0.48	-0.1	-0.22	0.25
Research Development	-0.15	-0.29	0.09	0.32	-0.13	0.98	-0.92	-0.91	-0.97	-0.14	0.97	-0.91	-0.13	-0.82	-0.92	-0.41		-0.02	-0.83	0.04	-0.32	0.01	-0.24	-0.01
Discontinued Operations	-0.14	-0.16	0.15	0.32	-0.88	-0.04	0.1	0.1	0.05	0.79	-0.23	0.12	0.11	0.09	0.12	-0.25	-0.02		0.11	0.13	-0.31	0.85	0.52	-0.8
Net Income From Continuing Ops	-0.3	0.26	-0.26	-0.27	-0.08	-0.83	0.96	0.94	0.83	0.23	-0.84	0.98	0.27	0.98	0.75	0.27	-0.83	0.11		0.1	0.34	0.15	0.08	-0.1
Non Operating Income Net Other	0.11	-0.35	-0.36	0.41	-0.18	-0.03	-0.08	-0.17	-0.12	-0.05	-0.03	0.05	0.88	0.07	-0.05	-0.35	0.04	0.13	0.1		-0.54	-0.05	0.26	-0.13
Interest Income	-0.2	0.53	-0.12	-0.64	0.35	-0.26	0.43	0.45	0.37	-0.04	-0.23	0.36	-0.32	0.38	0.31	0.48	-0.32	-0.31	0.34	-0.54		0.05	-0.61	0.31
Net Interest Income	-0.27	0.03	0.05	0.11	-0.82	-0.01	0.15	0.17	0.05	0.85	-0.21	0.15	0.02	0.15	0.13	-0.1	0.01	0.85	0.15	-0.05	0.05		0.25	-0.86
Reconciled Depreciation	0.1	-0.32	0.33	0.43	-0.46	-0.27	0.11	0.11	0.16	0.3	-0.33	0.14	0.15	0.05	0.28	-0.22	-0.24	0.52	0.08	0.26	-0.61	0.25		-0.41
Non Recurring	0.14	0.16	-0.04	-0.33	0.85	0.04	-0.09	-0.1	-0.04	-0.8	0.23	-0.11	-0.11	-0.09	-0.12	0.25	-0.01	-0.8	-0.1	-0.13	0.31	-0.86	-0.41

Click cells to compare fundamentals

Cocrystal Pharma Account Relationship Matchups

Cocrystal Pharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	46.2M	336K	382K	388K	(1.4M)	(1.3M)
Interest Expense	19K	8K	4K	2K	1.8K	1.7K
Selling General Administrative	4.9M	5.3M	5.4M	5.7M	6.0M	4.1M
Gross Profit	6.6M	1.8M	(239.5K)	(241.6K)	(15.2M)	(14.4M)
Other Operating Expenses	8.9M	11.6M	14.2M	18.1M	21.2M	22.7M
Operating Income	(48.4M)	(9.6M)	(14.2M)	(38.8M)	(18.6M)	(19.5M)
Ebit	(48.4M)	(9.6M)	(14.2M)	(38.8M)	(18.0M)	(18.9M)
Ebitda	(2.2M)	(9.3M)	(13.8M)	(38.4M)	(19.4M)	(20.3M)
Cost Of Revenue	4.0K	238.9K	239.5K	241.6K	15.2M	15.9M
Total Operating Expenses	8.9M	11.6M	14.2M	18.1M	3.4M	3.2M
Income Before Tax	(48.2M)	(9.6M)	(14.2M)	(38.8M)	(18.0M)	(18.9M)
Total Other Income Expense Net	237K	(62K)	36K	(8K)	575K	603.8K
Net Income	(48.2M)	(9.7M)	(14.2M)	(38.8M)	(18.0M)	(18.9M)
Income Tax Expense	(13.6M)	19K	8K	4K	(1.0)	(1.05)
Research Development	4.0M	6.3M	8.8M	12.4M	15.2M	22.4M
Net Income From Continuing Ops	(48.2M)	(9.6M)	(14.2M)	(38.8M)	(18.0M)	(18.9M)
Non Operating Income Net Other	769K	352K	256K	(54K)	(62.1K)	(65.2K)
Net Income Applicable To Common Shares	(48.2M)	(9.6M)	(14.2M)	(38.8M)	(35.0M)	(36.7M)
Net Interest Income	(19K)	(8K)	(4K)	(2K)	460K	483K
Reconciled Depreciation	254K	336K	382K	388K	412K	302.2K

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Cocrystal Stock

0.65	ME	23Andme Holding	Pair Corr
0.63	DOMH	Dominari Holdings	Pair Corr
0.62	DNTH	Dianthus Therapeutics	Pair Corr
0.61	DNLI	Denali Therapeutics	Pair Corr
0.61	VKTX	Viking Therapeutics	Pair Corr

The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.

The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cocrystal Historical Income Statement

About Cocrystal Income Statement Analysis

Cocrystal Pharma Income Statement Chart

Depreciation And Amortization

Gross Profit

Other Operating Expenses

Cocrystal Pharma income statement Correlations

Cocrystal Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cocrystal Pharma income statement Accounts

Pair Trading with Cocrystal Pharma

Moving against Cocrystal Stock

Additional Tools for Cocrystal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income
Research Development	+ 0.98	Other Operating Expenses
Net Income	+ 0.98	Income Before Tax
Net Income From Continuing Ops	+ 0.98	Income Before Tax
Net Income From Continuing Ops	+ 0.98	Net Income

Research Development	- 0.97	Ebitda
Ebitda	- 0.96	Other Operating Expenses
Total Operating Expenses	- 0.95	Ebitda
Research Development	- 0.92	Income Tax Expense
Income Before Tax	- 0.92	Total Operating Expenses
Research Development	- 0.92	Operating Income